Clinical Trial Update: BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating BCG with or without gefitinib in high-risk bladder cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• Gefitinib (Gefitinib)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Bladder Cancer | Phase 3 | Status: TERMINATED